natgillin/translations-raw huggingface dataset:
Hepatic Risk Management Guide, Patient Card
Smjernice za zbrinjavanje rizika za jetru, Kartica za bolesnika
Hepatic steatosis Hepatotoxicity Hepatomegaly
steatoza jetre hepatotoksičnost hepatomegalija
Hepatic steatosis is a risk factor for progressive liver disease including steatohepatitis and cirrhosis.
Steatoza jetre čimbenik je rizika za progresivnu bolest jetre uključujući steatohepatitis i cirozu.
hepatic steatosis, hepatitis
hepatička steatoza, hepatitis
Hepatic steatosis, hepatomegaly, cholangitis, hyperbilirubinemia
Steatoza jetre, hepatomegalija, kolangitis, hiperbilirubinemija
hepatic steatosis1, hepatitis1
jetrena steatoza1, hepatitis1
Hepatic toxicity (ALT or AST elevation), neutropenia
Intoksikacija jetre (porast ALT ili AST), neutropenija
Hepatic Toxicity (ALT, AST)
Jetrena toksičnost (ALT, AST)
Hepatic transaminase and bilirubin levels should be investigated before the initiation of treatment with Ofev, and periodically thereafter (e.g. at each patient visit) or as clinically indicated.
Razine jetrenih transaminaza i bilirubina se moraju ispitati prije početka liječenja Ofevom, te potom u određenim periodima (npr. pri svakom dolasku bolesnika na pregled) ili prema kliničkoj indikaciji.
Hepatic transaminase elevations
Povišene vrijednosti jetrenih transaminaza
Hepatic transaminase elevations
Povišenje vrijednosti jetrenih transaminaza
Hepatic transaminases increased
povišene vrijednosti jetrenih transaminaza
Hepatic transaminases increased, Weight increased, Total bilirubin increased*
povišene vrijednosti jetrenih transaminaza, povećanje tjelesne težine, povišenje ukupnog bilirubina
Hepatic transplant
Presađivanje jetre
Hepatic uptake of pixantrone is possibly mediated by OCT1 active transporters and biliary excretion by P-gp and BCRP.
U preuzimanju („uptake“) piksantrona u jetru vjerojatno sudjeluju aktivni transporteri OCT1 a u izlučivanju u žuč P-gp i BCRP.
Hepatic, renal, respiratory or other2 toxicities Grade 3 or 4
Hepatičke, renalne, respiratorne ili druge2 toksičnosti Stupanj 3 ili 4
Hepatically-impaired patients
Bolesnici s oštećenjem jetre
Hepatitis
hiperhidroza
hepatitis (0.2% vs 0.3%), hepatic steatosis (0.3% vs
hepatitis (0,2% prema 0,3%), hepatička steatoza (0,3
hepatitis (auto-immune) (may cause yellowing of the skin and eyes, dark coloured urine) difficulty of coordinating muscles
hepatitis (autoimuni) (može uzrokovati žutilo kože i očiju, tamno obojenu mokraću) poteškoće u koordinaciji mišića
hepatitis (autoimmune hepatitis and drug induced liver injury)
hepatitis (autoimuni hepatitis i ozljeda jetre uzrokovana primjenom lijeka)
Hepatitis (including
Hepatitis
hepatitis (including hepatic enzyme increased)
hepatitis (uključujući povećane razine jetrenih enzima)
Hepatitis (including hepatocellula r, cholestatic or mixed liver injury)11
hepatitis (uključujući hepatocelularno, kolestatsko ili mješovito oštećenje jetre)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 11
hepatitis (uključujući hepatocelularno, kolestatsko ili mješovito oštećenje jetre)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
EU/1/08/475/013 EU/1/08/475/014 EU/1/08/475/015 EU/1/08/475/016 EU/1/08/475/017 EU/1/08/475/039 EU/1/08/475/040 EU/1/08/475/049 EU/1/08/475/054 EU/1/08/475/055 EU/1/08/475/057 EU/1/08/475/062
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
hepatitis (uključujući hepatocelularno, kolestatsko ili miješano oštećenje jetre)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
mješovito oštećenje jetre)11
hepatitis (inflamation of the liver), jaundice (yellow of the skin or eyes)
hepatitis (upala jetre), žutica (žuta boja kože ili očiju)
Hepatitis (inflamed liver)
hepatitis (upala jetre)
hepatitis (inflammation of the liver)
hepatitis (upala jetre)
hepatitis (inflammation of the liver) anaphylactic shock (severe allergic reaction)
hepatitis (upala jetre) anafilaktički šok (teška alergijska reakcija)
hepatitis (inflammation of the liver) itching
hepatitis (upala jetre) svrbež
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB) (adsorbirano)
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB), adsorbirano
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB) (adsorbirano)
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB) (adsorbirano).
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB), adsorbirano
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA) (HAB), adsorbirano.
Hepatitis A virus (inactivated)1,2 360 ELISA Units Hepatitis B surface antigen3,4 10 micrograms
inaktivirani virus hepatitisa A 1,2 360 ELISA jedinica površinski antigen virusa hepatitisa B 3,4 10 mikrograma
Hepatitis A virus (inactivated)1,2 720 ELISA Units
Hepatitis A: Hepatitis A je zarazna bolest koja pogađa jetru.
Hepatitis A virus (inactivated)1,2 720 ELISA Units Hepatitis B surface antigen3,4 20 micrograms
inaktivirani virus hepatitisa A 1,2 720 ELISA jedinica površinski antigen virusa hepatitisa B 3,4 20 mikrograma
Hepatitis A virus (inactivated)1,2 720 ELISA Units Hepatitis B surface antigen3,4 20 micrograms
inaktivirani virus hepatitisa A1,2 720 ELISA jedinica površinski antigen hepatitisa B3,4 20 mikrograma
Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver.
Hepatitis A: Hepatitis A je zarazna bolest koja pogađa jetru.
Hepatitis A: Infection with the hepatitis A virus may cause the liver to become swollen (inflamed).
Hepatitis A: Infekcija virusom hepatitisa A može uzrokovati oticanje (upalu) jetre.
hepatitis acute
akutni hepatitis
Hepatitis and fatty liver
hepatitis i masna jetra
Hepatitis and hepatic events
Hepatitis i oštećenja jetre
hepatitis B (a viral liver infection);
hepatitisa B (virusne infekcije jetre);
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)
Cjepivo protiv hepatitisa B (rDNA) (s adjuvansom, adsorbirano)
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Cjepivo protiv hepatitisa B (rDNA) (s adjuvansom, adsorbirano)
Hepatitis B and/or C
hepatitis B i/ili C
Hepatitis B immunoglobulin has no or negligible influence on the ability to drive and use machines.
Imunoglobulin protiv hepatitisa B ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
Nakon izlaganja potrebno je čim prije primijeniti imunoglobulin protiv hepatitisa B (unutar 24 sata).
Hepatitis B immunological memory was confirmed in children 4 to 12 years of age.
Imunološka memorija protiv hepatitisa B potvrđena je u djece u dobi od 4-12 godina.
Hepatitis B infection and reactivation
infekcija hepatitisom B i reaktivacija hepatitisa B
Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles).
Infekcija hepatitisa B širi se spolnim odnosom s nekim tko ima infekciju ili putem zaražene krvi (primjerice korištenjem zaraženih injekcijskih igala).
Hepatitis B is a virus that infects the liver causes long term (chronic) infection,and can lead to liver damage.
Hepatitis B je virus koji zahvaća jetru, uzrokuje dugotrajnu (kroničnu) infekciju i može dovesti do njenog oštećenja.
Hepatitis B or C and are being treated with a combination of antiretroviral agents, as you are at a greater risk of a severe and potentially life threatening reaction because of the effect on the liver.
Hepatitis B ili C i liječite se kombinacijom antiretrovirusnih lijekova, jer ste izloženi većem riziku od teške i možda za život opasne reakcije zbog učinka na jetru.
Hepatitis B reactivation*
Ponovna aktivacija hepatitisa B
Hepatitis B reactivation11
Ponovna aktivacija hepatitisa B
Hepatitis B reactivitation
Ponovna aktivacija hepatitisa B
Hepatitis B surface antigen 1, 2, 3 20 micrograms
površinski antigen Hepatitisa B 1, 2, 3 20 mikrograma
Hepatitis B surface antigen2,3 10 micrograms Poliovirus (inactivated) type 1 (Mahoney strain)4 40 D-antigen unit type 2 (MEF-1 strain)4 8 D-antigen unit type 3 (Saukett strain)4 32 D-antigen unit
Površinski antigen virusa hepatitisa B2,3 10 mikrograma Poliovirus (inaktivirani) tip 1 (soj Mahoney)4 40 D-antigen jedinica tip 2 (soj MEF-1)4 8 D-antigen jedinica tip 3 (soj Saukett)4 32 D-antigen jedinice
Hepatitis B surface antigen2,3: 10 micrograms Poliovirus (Inactivated)4:
Pertaktin (PRN) 3 mikrograma
Hepatitis B surface antigen3,4 20 micrograms
Hepatitis A: Hepatitis A je zarazna bolest koja pogađa jetru.
Hepatitis B surface antigen5 10 micrograms
Površinski antigen virusa hepatitisa B5 10 mikrograma
Hepatitis B vaccine (rDNA)
Cjepivo protiv hepatitisa B (rDNA)
Hepatitis B virus (HBV) antiviral agents
Antivirusni lijekovi za virus hepatitisa B (HBV)
Hepatitis B Virus (HBV) co-infection
Koinfekcija virusom hepatitisa B (HBV)
Hepatitis B virus (HBV) infection and reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, has occurred in patients treated with drugs classified as CD20-directed cytolytic antibodies, including Arzerra.
U bolesnika liječenih lijekovima koji su svrstani u skupinu citolitičkih protutijela s ciljanim djelovanjem na CD20, uključujući lijek Arzerra, došlo je do infekcije virusom hepatitisa B (HBV) i njegove reaktivacije, koja je u nekim slučajevima uzrokovala fulminantni hepatitis, zatajenje jetre i smrt.
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with anti-CD20 antibodies including Gazyvaro (see section 4.8).
U bolesnika liječenih anti-CD20 protutijelima, uključujući lijek Gazyvaro, može doći do reaktivacije virusa hepatitisa B (HBV), što u nekim slučajevima može rezultirati fulminantnim hepatitisom, zatajenjem jetre i smrću (vidjeti dio 4.8).
Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with MabThera.
Sve bolesnike uvijek se mora prije početka liječenja lijekom MabThera testirati na HBV.
Hepatitis B virus surface antigen, recombinant (HBsAg) * ...................
Površinski antigen virusa hepatitisa B, rekombinantni (HBsAg) *........
Hepatitis B virus surface antigen, recombinant (HBsAg) * ...................
Površinski antigen virusa hepatitisa B, rekombinantni (HBsAg) *……….
Hepatitis B virus surface antigen, recombinant (HBsAg) * ....................
Površinski antigen virusa hepatitisa B, rekombinantni (HBsAg) *........
Hepatitis B, Infection*, Bronchopneumonia
Hepatitis B, infekcija*, bronhopneumonija
Hepatitis B: Approximately one quarter of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate, most of which are mild.
Hepatitis B: Može se očekivati da će približno jedna četvrtina pacijenata razviti nuspojave nakon liječenja tenofovirdizoproksilfumaratom, većina kojih su blage.
Hepatitis B: Infection with the hepatitis B virus may cause the liver to become swollen (inflamed).
Hepatitis B: Infekcija virusom hepatitisa B može uzrokovati oticanje (upalu) jetre.
Hepatitis B: Tell your doctor if the child has or has ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before the child begins treatment with Enbrel.
Hepatitis B: obavijestite svog liječnika ako dijete ima ili je ikad imalo hepatitis B. Nužno je da Vaš liječnik provede testiranje na prisutnost infekcije hepatitisom B prije nego što dijete započne liječenje Enbrelom.
Hepatitis B: Tell your doctor if you have or have ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before you begin treatment with Benepali.
Hepatitis B: Obavijestite svog liječnika ako imate ili ste ikad imali hepatitis B. Nužno je da Vaš liječnik provede testiranje na prisutnost infekcije hepatitisom B prije nego započnete liječenje Benepalijem.
Hepatitis B: Tell your doctor if you or the child have or have ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before you or the child begin treatment with Enbrel.
Hepatitis B: obavijestite svog liječnika ako Vi ili dijete imate ili ste ikad imali hepatitis B. Nužno je da Vaš liječnik provede testiranje na prisutnost infekcije hepatitisom B prije nego Vi ili dijete započnete liječenje Enbrelom.
Hepatitis C antivirals
Antivirusni lijekovi protiv hepatitisa C
Hepatitis C antivirals
Hepatitis C antivirusni lijekovi
Hepatitis C antivirals
klaritromicin:
Hepatitis C antivirals
koncentracija simeprevira u
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
ANTIVIRUSNI LIJEKOVI DIREKTNOG DJELOVANJA NA VIRUS HEPATITISA C (HCV)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
ANTIVIRUSNI LIJEKOVI IZRAVNOG UČINKA NA HEPATITIS C VIRUS (HCV)
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are co- administered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see section 4.3 and 4.5).
Antivirotici koji djeluju izravno na virus hepatitisa C (HCV): Kada se istodobno s fosamprenavirom/ritonavirom primjenjuju antivirotici koji djeluju izravno na virus hepatitisa C, a koji se metaboliziraju putem CYP3A4 ili inhibiraju/induciraju CYP3A4, očekuje se da će se promijeniti koncentracije lijekova u plazmi zbog inhibicije ili indukcije aktivnosti enzima CYP3A4 (vidjeti dijelove 4.3 i 4.5).
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are co- administered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see sections 4.3 and 4.5).
Antivirotici koji djeluju izravno na virus hepatitisa C (HCV): Kada se istodobno s fosamprenavirom/ritonavirom primjenjuju antivirotici koji djeluju izravno na virus hepatitisa C, a koji se metaboliziraju putem CYP3A4 ili inhibiraju/induciraju CYP3A4, očekuje se da će se promijeniti koncentracije lijekova u plazmi zbog inhibicije ili indukcije aktivnosti enzima CYP3A4 (vidjeti dijelove 4.3 i 4.5).
Hepatitis C: Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
Hepatitis C: obavijestite liječnika ako dijete ima hepatitis C. Vaš će liječnik možda htjeti pratiti liječenje Enbrelom u slučaju mogućeg pogoršanja infekcije.
Hepatitis C: Tell your doctor if you have hepatitis C. Your doctor may wish to monitor the treatment with Benepali in case the infection worsens.
Hepatitis C: Obavijestite liječnika ako imate hepatitis C. Vaš će liječnik možda htjeti pratiti liječenje Benepalijem u slučaju mogućeg pogoršanja infekcije.
Hepatitis C: Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
Hepatitis C: obavijestite liječnika ako Vi ili dijete imate hepatitis C. Vaš će liječnik možda htjeti pratiti liječenje Enbrelom u slučaju mogućeg pogoršanja infekcije.
hepatitis cholestatic
kolestatski hepatitis
Hepatitis Cvirus (HCV) antiviral agents
Antivirusni lijekovi za virus hepatitisa C (HCV)
Hepatitis including AST, ALT and GGT increases
Hepatitis, uključujući povišenje AST-a, ALT-a i GGT-a
Hepatitis including AST, ALT and GGT increases
Umor uključujući asteniju
Hepatitis led to discontinuation of pembrolizumab in 6 (0.2%) patients.
Hepatitis je doveo do prekida liječenja pembrolizumabom u 6 (0,2%) bolesnika.
Hepatitis occurred in 19 (0.7%) patients, including Grade 2, 3 or 4 cases in 4 (0.1%), 12 (0.4%) and
Hepatitis se javio u 19 (0,7%) bolesnika liječenih pembrolizumabom, uključujući slučajeve 2. stupnja u 4 (0,1%) bolesnika, slučajeve 3. stupnja u 12 (0,4%) bolesnika i slučajeve 4. stupnja u
hepatitis reactivation of hepatitis B
hepatitis reaktivacija hepatitisa B
hepatitis reactivation of hepatitis B1)
hepatitis reaktivacija hepatitisa B1) autoimuni hepatitis1)
hepatitis reactivation of hepatitis B1) autoimmune hepatitis1)
hepatitis reaktivacija hepatitisa B1) autoimuni hepatitis1)
Hepatitis toxic, hepatic failure, hepatic cirrhosis, blood alkaline phosphatase increased
Toksični hepatitis, zatajenje jetre, ciroza jetre, porast alkalne fosfataze
Hepatitis with mainly cholestatic features (see section 4.4)
Hepatitis s uglavnom kolestatskim obilježjima (vidjeti dio 4.4)
hepatitis with or without jaundice
hepatitis sa žuticom ili bez nje
hepatitis*, cytolytic hepatitis*
hepatitis*, citolitički hepatitis
Hepatitis*, Hyperbilirubinaemia*
hepatitis*, hiperbilirubinemija
hepatitis, cholecystitis, cholestasis
hepatitis, kolecistitis, kolestaza
hepatitis, cholelithiasisa, cholestasisa
hepatitis, kolelitijazaa, kolestazaa
hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
hepatitis, citolitički hepatitis, hepatička steatoza, hepatomegalija, povišene transaminaze, povišena aspartat aminotransferaza, povišen bilirubin u krvi, povišena alkalna fosfataza u krvi, povišena gama-glutamiltransferaza
Hepatitis, elevated liver function tests
Hepatitis, povišeni rezultati testova funkcije jetre
hepatitis, hepatic steatosis, hepatitis alcoholic, hepatic failure
hepatitis, hepatička steatoza, alkoholni hepatitis, zatajenje jetre
hepatitis, including reports of hepatic failure, pancreatitis.
hepatitis, uključujući prijave zatajenja jetre, pankreatitis
Hepatitis, jaundice
hepatitis, žutica
Hepatitis, jaundice*, liver injury*
Hepatitis, žutica*, oštećenje jetre
hepatitis, jaundice, hepatic enzyme elevations (mostly consistent with cholestasis)
hepatitis, žutica, povišene vrijednosti jetrenih enzima (uglavnom uvijek uz kolestazu)
Hepatitis, jaundice, hyperbilirubinaemia
hepatitis, žutica, hiperbilirubinemija
Hepatitis/jaundice Hepatic failure
Hepatitis/žutica Zatajenje jetre
hepatitis; reactivation of hepatitis B;
hepatitis, reaktivacija hepatitisa B,
Hepatitisa,am, jaundicea,am, hepatic enzymes increased (mostly consistent with cholestasis)am
Hepatitisa,am, žuticaa,am, povišeni jetreni enzimi (uglavnom upućuju na kolestazu)am
hepatitisb, hyperbilirubinaemia
hepatitisb, hiperbilirubinemija
Hepato biliary disorders
Poremećaji jetre i žuči
Hepato- biliary disorders
Poremećaji jetre i žuči
Hepato-biliary
Jetra i žuč
Hepato-biliary disorders
Bolesti jetre i žuči
Hepato-biliary disorders
Hepatobilijarni poremećaji
Hepato-biliary disorders
Poremećaji jetre i žuči
Hepato-biliary disorders
zatajenje jetre, kolangitis, masna jetra
Hepato-biliary disorders :
Poremećaji jetre i žuči:
Hepato-biliary disorders*
Poremećaji jetre i žuči
Hepato-biliary disorders:
Poremećaji jetre i žuči:
Hepatobiliary
Poremećaji jetre i žuči
Hepatobiliary disorder
Poremećaji jetre i žuči
Hepatobiliary disorders
Funkcija jetre
Hepatobiliary disorders
Hepatobilijarni poremećaji
Hepatobiliary disorders
jetre i žuči
Hepatobiliary disorders
Krvožilni poremećaji
Hepatobiliary disorders
Opći poremećaji
Hepatobiliary disorders
Poreme ćaji jetre i žuči
Hepatobiliary disorders
Poremeć aji jetre i žuči
Hepatobiliary disorders
Poremećaji
Hepatobiliary disorders
Poremećaji bubrega i mokraćnog sustava
Hepatobiliary disorders
Poremećaji imunološkog sustava
Hepatobiliary disorders
Poremećaji jetre
Hepatobiliary disorders
Poremećaji jetre i
Hepatobiliary disorders
Poremećaji jetre i ţuĉi
Hepatobiliary disorders
Poremećaji jetre i žući
Hepatobiliary disorders
Poremećaji jetre i žuči
Hepatobiliary disorders
Poremećaji jetre i žuči Nepoznata učestalost :
Hepatobiliary disorders
Poremećaji kože i potkožnog tkiva
Hepatobiliary Disorders
Poremećaji krvi i limfnog sustava
Hepatobiliary disorders
Poremećaji metabolizma i prehrane
Hepatobiliary disorders
Poremećaji mišićno
Hepatobiliary disorders
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Hepatobiliary disorders
Poremećaji živčanog sustava
Hepatobiliary disorders
Poremećaji žuči i jetre
Hepatobiliary disorders
Poremećaji žuči i jetre:
Hepatobiliary disorders
Pretrage
Hepatobiliary disorders
probavnog
Hepatobiliary disorders
uhoća kože
Hepatobiliary disorders
Znakovi i simptomi
Hepatobiliary disorders Common Liver function test abnormal (including transaminases increased)
Poremećaji jetre i žuči često abnormalni rezultati testova jetrene funkcije (uključujući povišene vrijednosti transaminaza)
Hepatobiliary disorders Renal and urinary disorders General disorders and administration site conditions
Poremećaji jetre i žuči Poremećaji bubrega i mokraćnog sustava
Hepatobiliary disorders Uncommon: Not known:
Poremećaji jetre i žuči Manje često: Nije poznato:
Hepatobiliary disorders*
Poremećaji jetre i žuči
Hepatobiliary disorders6
Poremećaji jetre i žuči6
Hepatobiliary disorders:
Poremećaji jetre i žuči
Hepatobiliary disorders:
Poremećaji jetre i žuči:
Hepatobiliary disorders:
Poremećaji mišićno-koštanog sustava i vezivnog tkiva:
Hepatobiliary disorders:
Poremećaji probavnog sustava:
Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (≥ 1/10,000 to < 1/1,000)).
Poremećaji jetre i žuči: kolestaza, hepatitis (uključujući hepatocelularno oštećenje) (u objedinjenim ispitivanjima faze III, ti su događaji bili rijetki (≥ 1/10,000 i < 1/1,000)).
Hepatobiliary disorders: common: jaundice; uncommon: hepatitis, cholelithiasisa, cholestasisa; rare: hepatosplenomegaly, cholecystitisa
Poremećaji jetre i žuči: često: žutica; manje često: hepatitis, kolelitijazaa, kolestazaa; rijetko: hepatosplenomegalija, kolecistitisa
Hepatobiliary Disorders: Hepatic decompensation, hepatic failure have been observed during treatment with Viekirax with and without dasabuvir and with or without ribavirin (see section 4.4).
Poremećaji jetre i žuči: Dekompenzacija jetre i zatajenje jetre primijećeni su tijekom liječenja lijekom Viekirax u kombinaciji s dasabuvirom ili bez njega i u kombinaciji s ribavirinom ili bez njega (vidjeti dio 4.4).
Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)
Poremećaji jetre i žuči Nije poznato: žutica (intrahepatička kolestatska žutica)
Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)
Poremećaji jetre i žuči: Nepoznato: žutica (intrahepatička kolestatska žutica)
Hepatobiliary disorders: Uncommon: Not known:
Poremećaji jetre i žuči: Manje često: žutica
Hepatobiliary system
Poremećaji jetre i žuči
Hepatobiliary tract
Hepatobilijarni trakt
Hepatobilliary disorders
Poremećaji jetre i žuči
hepatocellular carcinoma (11 April 2006)
hepatocelularni karcinom (11. travnja 2006.)
hepatocellular carcinoma (a type of liver cancer);
hepatocelularni karcinom (tip raka jetre);
Hepatocellular damage
hepatocelularno oštećenje
hepatocellular damage and hepatitis, cholestasis and jaundice
puteva, hepatocelularno oštećenje i hepatitis, kolestaza i žutica
hepatocellular damage including fatal cases (see section 4.4)
hepatocelularno oštećenje uključujući smrtne slučajeve (vidjeti dio 4.4)
hepatocellular damage, hepatitis, jaundice, hepatomegaly,
hepatocelularno oštećenje, hepatitis, žutica, hepatomegalija,
Hepatocellular damage/hepatitisi
hepatocelularno oštećenje/hepatitis
Hepatocellular Injury
ekhimoza
Hepatocellular injury
oštećenje jetrenih stanica
Hepatocellular injury, in rare cases with fatal outcome* (see section 4.4)
hepatocelularno oštećenje, u rijetkim slučajevima s fatalnim ishodom⃰ (vidjeti dio 4.4)
Hepatocellular injury; Jaundice; Hepatocellular failure
oštećenje jetre; žutica; hepatocelularno zatajenje